Tag: clinical
Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia
The largest Australian full-service CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client Tetherex Pharmaceuticals on first patient dosing for its Phase 1 vaccine clinical trial.Tetherex Pharmaceuticals, Inc. is a privately held, clinical stage biopharmaceutical company focused on development of selectin inhibitor therapeutics for the treatment of a broad range of inflammatory diseases and single-cycle adenovirus vaccines for multiple infectious diseases and cancer indications. Avance Clinical Chief Scientific Officer Dr Gabriel Kremmidiotis said: “The exciting aspect of the Tetherex product is the potential to vaccinate using a nasal spray. Administering ... Read more
Clinical Advances of RNAi Therapy Discussed at Oligonucleotide Therapeutics and Delivery Conference 2021
From optimizing particle size to choosing the right nanocarrier systems, Oligonucleotide Therapeutics and Delivery conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Download a copy of your brochure to find out who will be speaking at the upcoming conference in September www.oligonucleotide.co.uk/PRCOMpr4 Clinical Advances of RNAi Therapy Treating diseases with antibody oligonucleotide conjugates: Combining the selectivity of antibodies with the specificity of oligonucleotide drugs – Antibody oligonucleotide conjugates utilize the selectivity of antibody delivery and the specificity of oligonucleotide therapeutics to treat diseases– AOC1001 is designed to treat myotonic dystrophy type ... Read more
Japan – Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer’s Disease with Lecanemab, an Anti-Abeta Protofibril Antibody, in the peer-reviewed journal Alzheimer’s Research and Therapy. The manuscript describes results from Study 201, a Phase 2b proof- of-concept clinical trial that explored the impact of treatment with lecanemab (BAN2401) on reducing brain amyloid beta (Abeta) and clinical decline. The manuscript concluded that the pre-specified analysis showed consistent reduction of clinical decline across several clinical and biomarker endpoints at the highest doses, which the Phase 3 ... Read more